Spanish authorities on Friday were preparing to receive more than 140 passengers and crew members on board a hantavirus-stricken cruise ship headed for the Canary Islands.
Roche has signed a deal to acquire PathAI to speed up its use of artificial intelligence to help pathologists diagnose diseases.
Makary's ouster would create another high-profile vacancy atop RFK Jr.'s health department.
President Donald Trump has approved a plan to fire FDA Commissioner Marty Makary, M.D., according to a report from The Wall Street Journal.
During the weeklong stay by the Supreme Court to temporarily restore online access to the abortion pill mifepristone after a shock appeals court decision last Friday, scores of experts, industry heavyweights and former regulators have weighed in to defend the availability of the product.
With an FDA decision date looming for its Duchenne muscular dystrophy (DMD) treatment deramiocel, Capricor Therapeutics has filed a lawsuit against its U.S. commercial partner, NS Pharma, and its parent company, Nippon Shinyaku.
A common constipation drug may have unexpectedly unlocked a new way to slow chronic kidney disease — a condition that affects millions and often leads to dialysis. In a clinical trial involving 150 patients, researchers found that lubiprostone, a medication normally used to treat constipation, helped preserve kidney function in people with moderate CKD. Scientists traced the effect to changes in g
Scientists have uncovered a surprising way to influence the bacteria living in our mouths — not by killing them, but by interrupting how they “talk” to each other. Researchers found that dental plaque bacteria use chemical signals to coordinate growth, and by blocking those signals, they were able to encourage healthier bacteria while reducing disease-linked microbes tied to gum disease. Even more
Beneath the beauty of coral reefs lies a hidden universe of microbes unlike anything scientists expected. Each coral species supports its own specialized microbial partners, many of which have never been studied before. These microbes produce a stunning variety of chemical compounds with potential uses in medicine and biotech. The discovery highlights just how much is at stake as coral reefs face
“Fabricated” citations that do not reference real academic papers are spreading in the literature, polluting the public record of science, a new study found
Many cancer patients turn to biotin supplements hoping to restore hair lost during treatment, but experts warn the popular vitamin may do more harm than good. While biotin is often marketed for stronger hair and nails, there’s little evidence it actually helps cancer-related hair loss—and it can dangerously interfere with lab tests. Doctors say the supplement can distort key blood markers, potenti
A little-known tree from Brazil’s Atlantic Forest may hold a surprising weapon against COVID-19. Researchers discovered that compounds called galloylquinic acids, extracted from its leaves, can attack SARS-CoV-2 on multiple fronts—blocking the virus from entering cells, disrupting its replication, and even dampening harmful inflammation. Unlike many antivirals that target just one part of the viru
Here are key takeaways from a WHO briefing on the hantavirus outbreak aboard a cruise ship.
Eating eggs might do more than just start your day—it could help protect your brain. Researchers found that people 65 and older who eat eggs regularly have a significantly lower risk of developing Alzheimer’s disease, with daily or near-daily consumption linked to up to a 27% reduction. Even modest egg intake showed benefits, suggesting that small dietary changes could make a meaningful difference
This week on "The Readout LOUD" podcast: Seaport Therapeutics’ successful IPO, obesity pill battles, and the FDA commissioner's White House troubles.
Most researchers conduct their more disruptive work early in their careers, but as they age, they tend to abandon that groundbreaking energy
The hantavirus outbreak on the MV Hondius has focused the public's attention on cruise ship safety.
A political appointee gets in the way of a Sanofi drug's approval, and more from STAT's D.C. Diagnosis newsletter.
With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster Firdapse for $4.1 billion.
After a surprise rejection in January, the FDA has agreed to reconsider a T-cell therapy based on the same single-arm trial that the agency had previously found problematic. The case could reignite investors’ hope of a potential reversal for uniQure's high-profile gene therapy, too.